NCT05052671 ctDNA Assay in Patients With Resectable Pancreatic Cancer
| NCT ID | NCT05052671 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oklahoma |
| Condition | Pancreas Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2022-05-25 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2022-05-25 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the proportion of positive ctDNA -freely circulating tumor DNA fragments found in the blood plasma- in patients with pancreatic cancer and to better understand the relationship between possible ctDNA biomarkers and patient survival. A successful study may provide preliminary evidence that helps improve future patient care through targeted diagnostics, prognosis, and/or treatment.
Eligibility Criteria
Inclusion Criteria 1. Newly diagnosed exocrine pancreatic cancer with either pathology or radiology imaging suggestive of adenocarcinoma 2. Resectable/Borderline Resectable Pancreatic cancer as defined by the NCCN guidelines 3. ≥ 18 years old at the time of informed consent 4. ECOG Performance Status 0 or 1 5. Patients who are candidates for neoadjuvant chemo/chemoradiotherapy or upfront surgery are eligible for the study. 6. Ability to provide written informed consent and HIPAA authorization 7. Patients must have a life expectancy of at least 6 months Exclusion Criteria 1. Patients with pancreatic malignant tumor histologically confirmed as neuroendocrine or any other type of malignancies 2. Positive pregnancy test, pregnant, or breastfeeding 3. Any clinically significant and/or uncontrolled cardiac-related abnormality that would compromise patient safety or the outcome of the study 4. Locally advanced or metastatic disease
Contact & Investigator
Sagila George
PRINCIPAL INVESTIGATOR
University of Oklahoma
Frequently Asked Questions
Who can join the NCT05052671 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Pancreas Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05052671 currently recruiting?
Yes, NCT05052671 is actively recruiting participants. Contact the research team at SCC-IIT-office@ouhsc.edu for enrollment information.
Where is the NCT05052671 trial being conducted?
This trial is being conducted at Oklahoma City, United States, Tulsa, United States.
Who is sponsoring the NCT05052671 clinical trial?
NCT05052671 is sponsored by University of Oklahoma. The principal investigator is Sagila George at University of Oklahoma. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.